Ending HIV, Hepatitis, and STIs Demands Integrated Care, Scientific Breakthroughs, and Community Leadership, WHO Report Warns

GENEVA — The global fight against human immunodeficiency virus (HIV), viral hepatitis, and sexually transmitted infections (STIs) stands at a pivotal juncture. While medical science and expanded treatment access have driven historic reductions in mortality, critical gaps in healthcare delivery, funding disruptions, and systemic inequalities threaten to derail international elimination targets set for 2030.

In a comprehensive global progress report presented during the 26th International AIDS Conference and ahead of World Hepatitis Day, the World Health Organization (WHO) outlined a strategic road map to overcome these obstacles. The health agency emphasized that reaching elimination goals will require three unified pillars: integrating specialized care into primary healthcare systems, rapidly scaling scientific innovations, and empowering grassroots community leadership.

Progress and Setbacks: A Dual-Track Global Picture

Global public health interventions over the past decade have yielded significant victories, yet the distribution of these gains remains uneven.

According to the latest WHO global estimates, approximately 32 million people living with HIV were receiving lifesaving antiretroviral therapy (ART) by the end of 2025. Since 2010, annual new HIV infections worldwide have dropped by 42%, while AIDS-related mortality has plummeted by 57%.

Despite these advancements, an estimated 9 million people living with HIV still lack access to treatment. Furthermore, incidence rates are rising in several regions, predominantly impacting key populations—including men who have sex with men, sex workers, people who inject drugs, transgender individuals, and incarcerated populations—who frequently face severe stigma and barriers to care.

+-----------------------------------------------------------------------------------+
|                           GLOBAL PROGRESS AT A GLANCE                             |
+--------------------------+-----------------------+--------------------------------+
| Disease Indicator        | Historical Benchmark  | Recent Progress / Status       |
+--------------------------+-----------------------+--------------------------------+
| HIV Treatment Access     | --                    | 32 Million on ART              |
| HIV New Infections       | Baseline (2010)       | Decreased by 42%               |
| AIDS-Related Deaths      | Baseline (2010)       | Decreased by 57%               |
| Hepatitis B New Cases    | Baseline (2015)       | Decreased by 32%               |
| Hepatitis C Deaths       | Baseline (2015)       | Decreased by 12%               |
| Hepatitis Total Mortality| 2024 Estimate         | 1.3 Million Deaths Annually    |
+--------------------------+-----------------------+--------------------------------+

The trajectory for viral hepatitis presents a similarly complex picture. Annual new hepatitis B virus (HBV) infections have fallen by 32% since 2015, and global hepatitis C virus (HCV) mortality has decreased by 12%. However, viral hepatitis claimed an estimated 1.3 million lives in 2024, with hepatitis B-related deaths increasing by 17% since 2015 due to low diagnostic coverage and inadequate treatment access in high-burden regions.

Simultaneously, the global response to STIs faces growing resistance. While screening and human papillomavirus (HPV) vaccination coverage have improved in select countries, overall STI transmission rates continue to climb globally. Public health officials express heightened concern over antimicrobial resistance (AMR), particularly multi-drug resistant strains of Neisseria gonorrhoeae, which threaten to render standard antibiotic regimens ineffective.

Why Integration Matters: Breaking Down Vertical Health Silos

A core conclusion of the WHO report is that treating HIV, viral hepatitis, and STIs as isolated “vertical” disease programs is no longer a sustainable or effective model. Instead, the fastest route to disease elimination lies in integrating these specialized services directly into primary health care (PHC) networks.

Historically, patients often had to navigate separate facilities for HIV testing, hepatitis screening, and STI treatment. Integrated care models co-locate these services alongside routine primary care, maternal and child health clinics, tuberculosis (TB) management, sexual and reproductive healthcare, and non-communicable disease (NCD) screening.

Why Integrated Care Works: Individuals at risk for one sexually transmitted or blood-borne pathogen often share risk factors for others. A patient visiting a clinic for routine antenatal care or diabetes management can be screened for HIV, hepatitis B, and syphilis in a single visit—drastically reducing missed opportunities for early diagnosis and timely intervention.

Moreover, embedding disease control within broader primary care infrastructures enhances operational resilience. When external donor financing fluctuates or health systems face emergency disruptions, integrated programs maintain essential care continuity far better than standalone disease programs.

Scientific Innovations: A New Arsenal for Prevention

The WHO report highlights that achieving elimination goals requires swift, equitable rollout of novel biomedical tools. Two recent prophylactic modalities demonstrate significant promise in lowering transmission rates:

1. Long-Acting Injectable PrEP (Lenacapavir): Recommended by the WHO as an additional pre-exposure prophylaxis (PrEP) option, lenacapavir is a twice-yearly injectable capsid inhibitor. Clinical trials showed exceptional efficacy in preventing HIV infection. Following initial rollout protocols, lenacapavir is actively being introduced across 10 countries, with implementation plans underway in 14 additional nations.

2. Doxycycline Post-Exposure Prophylaxis (DoxyPEP): Following landmark clinical trials, the WHO issued its first formal recommendation approving doxycycline post-exposure prophylaxis. Targeted primarily at men who have sex with men and transgender women, taking 200 mg of doxycycline within 72 hours of unprotected sexual contact significantly reduces the incidence of syphilis and chlamydia, while offering moderate protection against gonorrhoea in specific clinical settings.

Independent public health analysts emphasize that while these medical breakthroughs represent major leaps forward, they are not standalone remedies. To maximize their real-world impact, novel biomedical options must be paired with comprehensive barrier methods (condoms), accessible diagnostic testing, patient counseling, structural risk-reduction strategies, and rigorous monitoring for potential drug resistance.

Community Leadership and Health Equity

A central message throughout the WHO assessment is that biomedical tools and integrated clinic structures are ineffective if care fails to reach marginalized populations. Community-led organizations remain essential because they possess the trust, cultural understanding, and proximity required to serve individuals overlooked by traditional health care systems.

The report urges member states to formalize community participation by incorporating community-generated data into national health surveillance systems. Tracking who is being left behind in real time enables health ministries to allocate resources more equitably.

“This report demonstrates what is possible when countries invest in health, communities, and science,” stated Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “However, these hard-won gains can easily be reversed by funding disruptions, humanitarian emergencies, and persistent inequalities.”

Echoing these concerns, Dr. Tereza Kasaeva, Director of WHO’s Global HIV, TB, Hepatitis, and STIs Department, noted that the report serves as a roadmap for national planning:

“This assessment is a practical guide for action. It is designed to help national policy leaders target financial and clinical investments precisely where they will yield the greatest public health impact.”

Implementation Challenges and Real-World Limitations

While the WHO report outlines an optimistic vision, significant structural hurdles remain.

• Funding Shortfalls: Cuts in international donor funding disrupted frontline prevention initiatives across multiple lower- and middle-income countries, leading to localized stockouts of oral PrEP and testing reagents.

• Low Diagnostic Coverage: Diagnosis rates for chronic hepatitis B remain dangerously low; less than 15% of infected individuals globally are aware of their status, preventing timely administration of antiviral therapies that prevent liver cirrhosis and hepatocellular carcinoma.

• Supply Chain and Cost Barriers: Innovations like long-acting injectable lenacapavir face cost constraints, manufacturing bottlenecks, and complex regulatory approval pathways in developing nations.

• Surveillance and Antimicrobial Resistance: Weak diagnostic infrastructure in resource-limited settings hinders global tracking of drug-resistant gonorrhoea, raising the risk of untreatable outbreaks.

Bridging the gap between international policy recommendations and clinical delivery in community health centers requires sustained political will, domestic health financing, and universal health coverage frameworks.

Practical Implications for Public Health and Patients

For healthcare consumers and patients, the WHO’s findings provide actionable guidance for personal health management:

• Proactive Screening: Many viral hepatitis infections and STIs progress asymptomatically during their early stages. Routine screening remains the most reliable method for detecting infections before long-term organ damage or secondary transmission occurs.

• Discussing Modern Prevention Options: Individuals who may be at elevated risk for HIV or STIs should consult healthcare providers about biomedical prevention options, including long-acting PrEP, daily oral PrEP, post-exposure prophylaxis options like doxyPEP, and barrier methods.

• Vaccination Coverage: Safe and highly effective vaccines exist for Hepatitis B and Human Papillomavirus (HPV). Ensuring full vaccination coverage provides lifelong protection against these cancer-causing viruses.

• Navigating Integrated Care: Patients are encouraged to seek primary care facilities that offer co-located services, where routine wellness checks, routine blood work, and sexual health screenings can be managed efficiently in a single medical setting.

References

1. World Health Organization. WHO: Integration, innovation and community leadership key to ending HIV, hepatitis and STIs. News release. Published July 27, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.